



PATENT
Docket No. 265.00090101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Pasricha et al.)
Serial No.: 09/834,110)
Confirmation No.: 5306)
Filed: April 12, 2001)
For: TREATMENT OF DISORDERS BY IMPLANTING STEM CELLS AND/OR
PROGENY THEREOF INTO GASTROINTESTINAL ORGANS

Group Art Unit: 1632
Examiner: Joseph Woitach

FACSIMILE TRANSMISSION TO THE PTO

Commissioner for Patents
Attn: MAIL STOP ISSUE FEE
P.O. Box 1450
Alexandria, VA 22313-1450

FAX NUMBER: (703) 746-4000
Total Pages (including cover page): 6
Time: 3:15pm (Central Time)
(Transmission must be complete by
midnight eastern time.)

The following papers are being transmitted to the Patent and Trademark Office by facsimile transmission: Notice of Allowance (PTOL-85) Page 1 (1 pg.); Issue Fee Transmittal Part B (PTOL-85) (1 pg. in duplicate); Comments on Statements for Reasons of Allowance (2 pgs.)

X Small Entity Status is entitled to be asserted in the above-identified application.

Please charge Deposit Account No. 13-4895 in the following amounts:

\$665.00 - Issue Fee
\$300.00 - Publication Fee
\$9.00- Advanced Patent Copies

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Mueting, Raasch & Gebhardt, P.A.

Customer Number: 26813

Sept. 8, 2004
Date

By: Ann M. Mueting
Ann M. Mueting
Reg. No. 33,977
Direct Dial (612)305-1217

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to the Commissioner for Patents, Attn: Mail Stop Issue Fee, P.O. Box 1450, Alexandria, VA 22313-1450, on this 8th day of September, 2004, at 3:15pm (Central Time).

September 8, 2004
Date

Signature: SAUNE OLSON
Name: SAUNE OLSON

If you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax).



PATENT
Docket No. 265.00090101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Pasricha et al.)	Group Art Unit:	1632
)		
Serial No.: 09/834,110)	Examiner:	Joseph Voitach
Confirmation No.: 5306)		
)		
Filed: April 12, 2001)		
)		
For:)		
TREATMENT OF DISORDERS BY IMPLANTING STEM CELLS AND/OR PROGENY THEREOF INTO GASTROINTESTINAL ORGANS			

COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

Commissioner for Patents
Mail Stop ISSUE FEE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Notice of Allowance with its enclosed Examiner's Statement of Reasons for Allowance, mailed June 8, 2004, has been received and renewed. Applicants provide the following comments on the Examiner's Statement of Reasons for Allowance.

Telephonic interviews were held between Examiner Joseph Voitach and Applicants' Representative, Nancy Johnson, on March 11, 2004 and March 18, 2004. In these conversations, Examiner Voitach indicated that claims drawn to implanting isolated embryonic neural stem cells directly into the gastrointestinal alimentary tract of a subject, wherein the implanted embryonic neural stem cells produce nitric oxide, would be allowable. Examiner Voitach is thanked for the courtesy of initiating these telephone conversations.

Applicants thank the Examiner for the withdrawing of the election of species requirement. Applicants agree with the Examiner's statement that "[t]he search and consideration of the method encompassed by the pending claims would be coextensive for any type of disorder of the gastrointestinal alimentary tract as long as the disorder is associated with lower levels of nitric oxide" (Notice of Allowance, mailed June 8, 2004). However, Applicants do not understand the Examiner's extremely broad statement that "any type of disorder known in

Comments on Statement for Reasons of Allowance

Page 2

Serial No. 09/834,110

Filed: April 12, 2001

Allowed: June 8, 2004

Title: TREATMENT OF DISORDERS BY IMPLANTING STEM CELLS AND/OR PROGENY THEREOF INTO GASTROINTESTINAL ORGANS

the art associated with lower levels of nitric oxide" would be an obvious target for treatment by the presently claimed methods (Notice of Allowance, mailed June 8, 2004). This is not necessarily relevant to the allowed claims and we reserve the right to address this statement in a continuing application.

With the Reasons for Allowance, the Examiner asserted that amending "the claims to delete 'progeny thereof' and more specifically defining the stem cell delivered and the result of providing NO has differentiated the claimed method from that disclosed by Huo *et al.* and Keller *et al.* (Notice of Allowance, mailed June 8, 2004). For reasons already of record (see Amendment and Response filed July 25, 2004, pages 14-15, and Amendment and Response filed March 18, 2004, pages 7-8), Applicants continue to respectfully submit that the method of claims 21, 22, 25, 26, 28-32, as originally presented, are not anticipated by either Huo *et al.* or Keller *et al.*

Respectfully submitted for
Pasricha et al.

By
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612) 305-1220
Facsimile: (612) 305-1228
Customer Number 26813

Sept. 8, 2004
Date

By: Ann M. Mueting
Ann M. Mueting
Reg. No. 33,977
Direct Dial (612) 305-1217

CERTIFICATE UNDER 37 CFR §1.8:

The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to Commissioner for Patents, Mail Stop Issue Fee, P.O. Box 1450, Alexandria, VA 22313-1450, on this 8th day of September, 2004, at 3:15pm (Central Time).

By: Sam E. Dison
Name SAM E. DISON